FIRE-3: Kindling for a CRC Practice Change?FIRE-3: Kindling for a CRC Practice Change?

Dr. David Kerr reports on provocative data from the FIRE-3 study indicating that cetuximab plus FOLFIRI confers a 7.5-month survival advantage in patients with wild-type KRAS colorectal cancer. Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news